You are here: Industry Insights > VLP

News List

Icosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares firstwordpharma
August 03, 2021
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases.
Allergy Therapeutics launches biomarker study of peanut allergy vaccine candidate pharmatimes
January 07, 2021
Allergy Therapeutics has initiated a biomarker study at Imperial College London, which will aim to evaluate its novel virus like particle (VLP) based peanut allergy vaccine candidate.
Premas Biotech initiates triple antigen VLP COVID-19 vaccine candidate for animal trials expresspharma
July 09, 2020
At the moment, it is the only one from India to adopt a triple-antigen approach that is designed to produce an enhanced immune response.
Premas Biotech announces completion of vaccine prototype of triple-antigen candidate against COVID-1 expresspharma
May 20, 2020
Reportedly, the vaccine prototype is among the first in the world for VLP of SARS CoV-2 virus.